SpyGlass Pharma Inc. Common Stock (SGP)
Stock · NASDAQ · Health Care
$24as of 10/16/2026
Price chart
About SGP
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP)…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 76
- Website
- spyglasspharma.com/
Fundamentals
- 1-day range
- $24.68$27.11
- Market cap
- $827.48M
- P/E (trailing)
- —
- P/E (forward)
- -9.17
- EPS (trailing)
- $-3.37
- Dividend yield
- —
- Beta
- 1.20
- Avg. volume
- 112.5K
52-week range
$17.06$32.44
Next earnings: November 5, 2026 · EPS estimate $-0.62
Forecasts
6 analyst ratings
Buy 90%
Hold 10%
Sell 0%
1-year price forecast
High
$62
+158.3%
Median
$42
+75.0%
Low
$37
+54.2%
SpyGlass Pharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SGPSpyGlass Pharma Inc. Common Stock$24▼ 2.91%Market cap $827.48MP/E —$17.06$32.44
- SIBNSI-BONE Inc. Common Stock$19.68▼ 1.16%Market cap $813.01MP/E —$11.48$21.89
- SSIISS Innovations International Inc. Common Stock$2.53▼ 1.94%Market cap $742.49MP/E —$2.57$10
- TCMDTactile Systems Technology Inc. Common Stock$22.52▼ 3.31%Market cap $650.97MP/E 21.02$14.43$37.77
- BBNXBeta Bionics Inc. Common Stock$16.35▼ 5.55%Market cap $634.80MP/E —$8.8$32.71
- BWAYBrainsWay Ltd. American Depositary Shares$11.44▼ 3.21%Market cap $626.52MP/E 53.55$2,391$5,123
- ANGOAngioDynamics Inc. Common Stock$11.24▼ 2.94%Market cap $624.53MP/E —$9.39$16.29
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SGP SpyGlass Pharma Inc. Common Stock | $827.48M | — | $24 | ▼ 2.91% | $17.06$32.44 |
| SIBN SI-BONE Inc. Common Stock | $813.01M | — | $19.68 | ▼ 1.16% | $11.48$21.89 |
| SSII SS Innovations International Inc. Common Stock | $742.49M | — | $2.53 | ▼ 1.94% | $2.57$10 |
| TCMD Tactile Systems Technology Inc. Common Stock | $650.97M | 21.02 | $22.52 | ▼ 3.31% | $14.43$37.77 |
| BBNX Beta Bionics Inc. Common Stock | $634.80M | — | $16.35 | ▼ 5.55% | $8.8$32.71 |
| BWAY BrainsWay Ltd. American Depositary Shares | $626.52M | 53.55 | $11.44 | ▼ 3.21% | $2,391$5,123 |
| ANGO AngioDynamics Inc. Common Stock | $624.53M | — | $11.24 | ▼ 2.94% | $9.39$16.29 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Institutional Ownership
March 31, 2026
- Total shares held
- 24.71M
- Total value held
- $621.95M
- Institutional holders
- 31
Top holders this quarter
- Unknown8.02M
- Unknown7.39M
- Unknown2.50M
- Unknown2.11M
- Unknown704.4K
- Unknown666.8K
- Unknown550.0K
- Unknown468.8K
- Unknown434.8K
- Unknown375.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
SpyGlass Pharma Schedules Upcoming Investor Conference Participation
SpyGlass Pharma has announced its participation in upcoming investor conferences, a routine corporate engagement where company leadership typically meets with institutional investors and analysts to discuss business performance and outlook. The stock is currently trading near the upper end of its 52-week range of $17.06 to $32.44, with the average analyst price target standing at $44.00 based on six analyst estimates. Technical indicators show elevated momentum readings alongside a recent Bollinger band breakout, reflecting recent market interest in the pharmaceutical company's shares.
SpyGlass Pharma Schedules Upcoming Investor Conference Participation. SpyGlass Pharma has announced its participation in upcoming investor conferences, a routine corporate engagement where company leadership typically meets with institutional investors and analysts to discuss business performance and outlook. The stock is currently trading near the upper end of its 52-week range of $17.06 to $32.44, with the average analyst price target standing at $44.00 based on six analyst estimates. Technical indicators show elevated momentum readings alongside a recent Bollinger band breakout, reflecting recent market interest in the pharmaceutical company's shares.